Filtered By:
Cancer: Cancer
Therapy: Hormone Replacement Therapy

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 76 results found since Jan 2013.

The effect of growth hormone replacement in patients with hypopituitarism on pituitary tumor recurrence, secondary cancer, and stroke
AbstractGrowth hormone replacement therapy has benefits for patients with hypopituitarism. The safety profile in regard to tumor recurrence or progression, development of secondary malignancies, or cerebrovascular stroke is still an area of debate. A comprehensive search of multiple databases —MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, and Scopus was conducted through August 2015. Eligible studies that evaluated long-term adverse events in adult patients with hypopituitarism treated with growth hormone replacement therapy a nd reported development of pituitar...
Source: Endocrine - November 3, 2016 Category: Endocrinology Source Type: research

HRT optimization, using transdermal estradiol plus micronized progesterone, a safer HRT.
Abstract ABSTRACT Hormone replacement therapy (HRT) remains the gold standard for treatment of climacteric symptoms in menopausal women; it is relatively safe in healthy subjects for at least 5 years, provided it had been initiated before the age of 60 years and/or within 10 years from menopause. Estrogen probably adds some cardioprotection, that can, however, be obscured by progestogens, especially medroxyprogesterone acetate (MPA). Oral HRT is associated with an increased risk of venous thromboembolism (VTE), gallbladder disease and possibly stroke. The increased occurrence of all these events can be prevented b...
Source: Climacteric - July 19, 2013 Category: Geriatrics Authors: L'hermite M Tags: Climacteric Source Type: research

Can HRT in early menopause cut heart disease risk?
ConclusionThis double-blind RCT found that women taking HRT less than six years after the menopause had slower artery wall thickening than those taking a placebo. This represented the main measure of atherosclerosis progression tested; other measures showed no difference, so the results were not as conclusive as they could have been. Women taking HRT 10 or more years after menopause also showed no difference in atherosclerosis progression compared with a placebo, further complicating the picture.An important limitation of this study is the lack of a patient relevant endpoint, such as cardiovascular events or mortality. Pre...
Source: NHS News Feed - April 1, 2016 Category: Consumer Health News Tags: Heart/lungs Medication Source Type: news

In recently postmenopausal women, HRT reduced a composite of death, MI, or heart failure at 10 years.
CONCLUSION In recently postmenopausal women, hormone replacement therapy reduced a composite of death, myocardial infarction, or heart failure after 10 years of therapy and an additional 6 years of follow-up.Hormone replacement therapy (HRT) vs no HRT in recently postmenopausal women†OutcomesEvent ratesAfter 10 y of therapyHRTNo HRTRRR (95% CI)NNT (CI)Death, MI, or HF‡3.2%6.5%50% (11 to 72)31 (22 to 144)At 16 yDeath, MI, or HF§6.6%11%37% (4 to 59)26 (17 to 251)†HF = heart failure; MI = myocardial infarction; other abbreviations defined in Glossary. RRR, NNT, and CI calculated from event rates and hazard ratios in ar...
Source: Annals of Internal Medicine - February 19, 2013 Category: Internal Medicine Authors: Cheung AM Tags: Ann Intern Med Source Type: research

Hormone replacement therapy in menopause
Embora o estrógeno já esteja disponível para venda há mais de seis décadas, as mulheres ainda permanecem confusas quanto ao risco e aos benefícios da terapia hormonal na menopausa (THM), terapia estrogênica isolada ou associada a progestágenos. A publicação de estudos controlados, randomizados, como o Heart and Estrogen/progestin Replacement Study (HERS) e Women’s Health Initiative (WHI), intensificou essa controvérsia risco/benefício. Milhares de mulheres são tratadas com THM para alívio dos sintomas menopausais, incluindo sintomas vasomotores e sudorese, principal indicação da estrogenoterapia. Outras p...
Source: Arquivos Brasileiros de Endocrinologia e Metabologia - May 14, 2014 Category: Endocrinology Source Type: research

Being happy 'won't help you live longer' survey finds
ConclusionThis large prospective study aimed to assess whether happiness or related measures of wellbeing are associated with risk of death, after allowing for the influence of the poor health and lifestyles of people who are unhappy.The study found poor health was linked with unhappiness in middle-aged women. However, after allowing for this association and adjusting for the influence of other factors that may be associated, such as smoking and poor socioeconomic status, happiness and related measures of wellbeing do not appear to have any direct effect on death. This suggests that, as has sometimes previously been specu...
Source: NHS News Feed - December 11, 2015 Category: Consumer Health News Tags: Lifestyle/exercise Mental health Source Type: news

Cardiovascular Programming During and After Diabetic Pregnancy: Role of Placental Dysfunction and IUGR
This study demonstrated that the incidence of ischemic heart disease and death were three times higher among men with low birth weight compared to men with high birth weight (5). Epidemiological investigations of adults born at the time of the Dutch famine between 1944 and 1945 revealed an association between maternal starvation and a low infant birth weight with a high incidence of hypertension and coronary heart disease in these adults (23). Furthermore, Painter et al. reported the incidence of early onset coronary heart disease among persons conceived during the Dutch famine (24). In that regard, Barker's findin...
Source: Frontiers in Endocrinology - April 8, 2019 Category: Endocrinology Source Type: research

How Menopause Affects Cholesterol —And How to Manage It
Kelly Officer, 49, eats a vegan diet and shuns most processed foods. So, after a recent routine blood test revealed that she had high cholesterol, “I was shocked and upset,” she says, “since it never has been [high] in the past.” Officer is not alone. As women enter menopause, cholestrol levels jump—by an average of 10-15%, or about 10 to 20 milligrams per deciliter. (A healthy adult cholesterol range is 125-200 milligrams per deciliter, according to the National Library of Medicine.) This change often goes unnoticed amidst physical symptoms and the general busyness of those years. But, says D...
Source: TIME: Health - September 21, 2022 Category: Consumer Health News Authors: Katherine Harmon Courage Tags: Uncategorized freelance healthscienceclimate heart health Source Type: news

The Timing Hypothesis and Hormone Replacement Therapy: A Paradigm Shift in the Primary Prevention of Coronary Heart Disease in Women. Part 2: Comparative Risks
A major misperception concerning postmenopausal hormone replacement therapy (HRT) is that the associated risks are large in magnitude and unique to HRT, but over the past 10 years, sufficient data have accumulated so that the magnitude and perspective of risks associated with the primary coronary heart disease prevention therapies of statins, aspirin, and postmenopausal HRT have become more fully defined. Review of randomized controlled trials indicates that the risks of primary prevention therapies and other medications commonly used in women's health are of similar type and magnitude, with the majority of these risks ca...
Source: Journal of the American Geriatrics Society - May 20, 2013 Category: Geriatrics Authors: Howard N. Hodis, Wendy J. Mack Tags: Updates on Aging Source Type: research

Could Antibodies or Hormones Slow Brain Damage from Alzheimer’s?
Scientists have discovered that certain antibodies may help slow the progression of Alzheimer’s disease. Dr. Patricia Salinas of University College London, UK, and her team focused on a protein called Dkk1, present in raised levels in the brains of people with Alzheimer’s disease. Using brain samples from mice, the team looked at the progressive disintegration of synapses in the hippocampus when exposed to a protein called amyloid-beta, thought to be central to the development of Alzheimer’s disease. “Synaptic loss mediated by amyloid-beta in early stages of the disease might contribute to cognitive...
Source: Psych Central - June 1, 2013 Category: Psychiatry Authors: Jane Collingwood Tags: Aging Alzheimer's Disorders General Seniors Abnormal Deposits Alzheimer S Disease Antibodies Brain Area Brain Damage Cognitive Decline Cognitive Impairments Disintegration Dr Patricia Dr Simon Hippocampus Journal Of Neurosc Source Type: news

Drugs to be offered to women at high risk of breast cancer
The National Institute of Health and Care Excellence (NICE) has today released updated guidelines on the care of women who are at increased risk of breast cancer due to their family history. One of the main changes to the original guidance from 2004 is that NICE now recommends drug treatment with tamoxifen or raloxifene to reduce risk of breast cancer in a specific group of women who are at high risk of breast cancer and have not had the disease. They say that these treatments could help prevent breast cancer in about 488,000 women aged 35 years and older. The updated guideline has also made changes to the recommende...
Source: NHS News Feed - June 25, 2013 Category: Consumer Health News Tags: Cancer Medical practice QA articles Source Type: news

C-reactive protein and fracture risk: European Prospective Investigation into Cancer Norfolk Study
Conclusion: A U-shaped association was observed between CRP and fracture risk. The increased risk of fracture observed at lower end of CRP compared to intermediate levels require further exploration, confirmation in other populations, and investigation into potential biological mechanisms.Highlights:
Source: Bone - July 17, 2013 Category: Orthopaedics Authors: Sara Ahmadi-Abhari, Robert N. Luben, Nicholas J. Wareham, Kay-Tee Khaw Tags: Original Articles Source Type: research

Time trends in pulmonary embolism: A matter of age and gender
Venous thromboembolism (VTE) is the third most common cardiovascular disease . Pulmonary embolism (PE) is potentially lethal and is the most serious manifestation of VTE . Notably, PE is the leading preventable cause of death in hospitalized patients , and is the third most common cardiovascular cause of death after myocardial infarction and stroke in Western world . Risk factors for VTE and PE include old age, surgery, immobilization, trauma, fractures, cancer, pregnancy, puerperium, oral contraceptive pill (OCP) use, and hormone replacement therapy (HRT) . Genetic factors are also important in VTE risk and family history...
Source: Thrombosis Research - June 24, 2013 Category: Hematology Authors: Bengt Zöller Tags: Editorials Source Type: research

Still a place for hormone replacement therapy?
Abstract Hormone replacement therapy (HRT) remains the most efficient treatment to alleviate climacteric symptoms. The drastic decline in their prescription following the WHI is not fully justified. Benefits might be more important than harm in women 50-60 years. French way of treatment does not increase the risk in thrombosis nor stroke and breast cancer risk is less important than with other regimen. One of the major benefits of HRT is the decrease in type 2 diabetes with all the treatments including the French ones. The results of the American randomized trials cannot be fully extrapolated to young postmenopa...
Source: Presse Medicale - November 7, 2013 Category: Journals (General) Authors: Gompel A Tags: Presse Med Source Type: research

Female sex as a risk factor for thromboembolism and death in patients with incident atrial fibrillation. The prospective Danish Diet, Cancer and Health study.
In conclusion, in a relatively young population of patients with atrial fibrillation, female sex was associated with a lower risk of thromboembolism and death. PMID: 25055988 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - July 24, 2014 Category: Hematology Authors: Overvad TF, Rasmussen LH, Skjøth F, Overvad K, Albertsen IE, Lane DA, Lip GY, Larsen TB Tags: Thromb Haemost Source Type: research